Securing OT & IoT
in Pharmaceutical Operations
Securing OT & IoT in Pharma Operations
Gain visibility into your multi-party supply chain, while protecting production processes and corporate IP from cyberattacks.
Pharmaceutical companies are embracing digital transformation, outsourcing and acquisition as fast paths to innovation and efficiency. But the complex web of business partners, production processes and OT and IoT networks creates operational visibility challenges and increases OT security risks.
See
All OT and IoT assets and behavior on your networks for unmatched awareness
Detect
Cyber threats, vulnerabilities, risks and anomalies for faster response
Unify
Security, visibility and monitoring across all your assets for improved resilience
Which OT / IoT Security Challenge is Keeping You Awake at Night?
CHALLENGE
Gaining Visibility into a Fragmented Supply Chain
Supply chain outsourcing and acquisitions make it hard to monitor and secure our production processes from end-to-end.
CHALLENGE
Assessing Risk in My Manufacturing Environment
How will patching, device misconfigurations or new OT and IoT security measures impact our production processes and standards compliance?
CHALLENGE
Defending Valuable Corporate IP From Cyber Espionage
To protect my business data, formulas and other IP from prying eyes, I need to secure my corporate and OT/IoT systems.
CHALLENGE
Detecting Malware Operating Within My IT/OT Networks
To prevent malware from spreading throughout my plants, I need lightning fast threat and anomaly detection.
Deployed in 7 of the top 10 global pharmaceutical companies.
Sample Deployment Architecture for Pharmaceutical Companies
You can tailor the Nozomi Networks solution to meet your needs by utilizing its flexible architecture and integrations with other systems.
Additionally, Remote Collectors™ can be added to Guardian sensors to capture data from third-party facilities.
The High Cost of a Cyber Incident
COMPANY
Multinational Pharma
CYBER INCIDENT
Ransomware: NotPetya
IMPACT
-
Production shutdown
-
Inability to fulfill vaccine orders, lost and backlogged sales
-
Increased marketing, administrative expenses and production costs
-
Technology remediation